Compare MARPS & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MARPS | IMRN |
|---|---|---|
| Founded | 1956 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 7.7M |
| IPO Year | N/A | 2016 |
| Metric | MARPS | IMRN |
|---|---|---|
| Price | $4.21 | $0.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.6K | ★ 17.4K |
| Earning Date | 11-13-2026 | 08-28-2026 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.05 | $0.68 |
| 52 Week High | $6.49 | $1.99 |
| Indicator | MARPS | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 42.09 |
| Support Level | $4.17 | $0.77 |
| Resistance Level | $4.58 | $1.00 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 28.30 | 46.15 |
Marine Petroleum Trust is a U.S .-based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of America. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.